Cargando…
Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871271/ https://www.ncbi.nlm.nih.gov/pubmed/35200588 http://dx.doi.org/10.3390/curroncol29020089 |
_version_ | 1784656956974170112 |
---|---|
author | Law, Jeanna Wallenta Mitra, Debanjali Kaplan, Henry G. Alfred, Tamuno Brufsky, Adam M. Emir, Birol McCracken, Haley Liu, Xianchen Broome, Ronda G. Zhang, Chenan DiCristo, Caroline Chen, Connie |
author_facet | Law, Jeanna Wallenta Mitra, Debanjali Kaplan, Henry G. Alfred, Tamuno Brufsky, Adam M. Emir, Birol McCracken, Haley Liu, Xianchen Broome, Ronda G. Zhang, Chenan DiCristo, Caroline Chen, Connie |
author_sort | Law, Jeanna Wallenta |
collection | PubMed |
description | This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC. |
format | Online Article Text |
id | pubmed-8871271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88712712022-02-25 Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network Law, Jeanna Wallenta Mitra, Debanjali Kaplan, Henry G. Alfred, Tamuno Brufsky, Adam M. Emir, Birol McCracken, Haley Liu, Xianchen Broome, Ronda G. Zhang, Chenan DiCristo, Caroline Chen, Connie Curr Oncol Article This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC. MDPI 2022-02-12 /pmc/articles/PMC8871271/ /pubmed/35200588 http://dx.doi.org/10.3390/curroncol29020089 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Law, Jeanna Wallenta Mitra, Debanjali Kaplan, Henry G. Alfred, Tamuno Brufsky, Adam M. Emir, Birol McCracken, Haley Liu, Xianchen Broome, Ronda G. Zhang, Chenan DiCristo, Caroline Chen, Connie Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
title | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
title_full | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
title_fullStr | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
title_full_unstemmed | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
title_short | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
title_sort | real-world treatment patterns and clinical effectiveness of palbociclib plus an aromatase inhibitor as first-line therapy in advanced/metastatic breast cancer: analysis from the us syapse learning health network |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871271/ https://www.ncbi.nlm.nih.gov/pubmed/35200588 http://dx.doi.org/10.3390/curroncol29020089 |
work_keys_str_mv | AT lawjeannawallenta realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT mitradebanjali realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT kaplanhenryg realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT alfredtamuno realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT brufskyadamm realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT emirbirol realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT mccrackenhaley realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT liuxianchen realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT broomerondag realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT zhangchenan realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT dicristocaroline realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT chenconnie realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork |